On their website they don't mention any planned interim analyses; however, they did release some interim results on June 1, 2015. Also, I note the following form ClinicalTrials.gov: "Interim analyses to assess efficacy are incorporated in the trial design." So I'm satisfied that we could have an AA based upon IA.
In taking a look at how Intercept (ICPT) gained AA in early 2014, it was after a pre-planned interim efficacy analysis. Am I correct in that NWBO does not have a pre-planned interim analysis? And that leads me to the question, is AA dependent on a formal pre-planned interim analysis? Sorry, more questions than answers but I'm hoping someone out there is more insightful than myself on this topic.